The use of weight loss drugs like Ozempic and Wegovy has surged in recent years. But the medications are not foolproof, as ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...